Articles tagged "HLA antibodies"

2021 American Transplant Congress
Impact of Bacterial Infection on HLA Allosensitization Among Kidney Recipients on the Waitlist
D. P. Cina¹, K. R. Sherwood², S. Dobrer², J. Wong³, F. Fenninger², M. Kadatz⁴, P. Keown⁴, J. Lan⁴
¹Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Department of Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada, ⁴Department of Nephrology, University of British Columbia, Vancouver, BC, Canada
*Purpose: The clinical relevance of HLA allosensitization associated with bacterial infection remains poorly defined. The primary objective of this study is to determine the incidence,…
2021 American Transplant Congress
An HLA Class II Matching Strategy That Predicts De Novo Donor-specific HLA Antibody Formation Using Low Resolution HLA Types
L. Hidalgo¹, I. Martinez Juarez², L. Morales Buenrostro², S. Shojai³, P. Campbell¹
¹University of Wisconsin Madison, Madison, WI, ²Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubrian, Mexico City, Mexico, ³Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: The development of de novo donor-specific HLA antibodies (dnDSA) is predominantly against HLA-Class II antigens and is a function of the degree of HLA-DQ…
2021 American Transplant Congress
Anti-HLA-DP Antibodies Positive – A Retrospective Review of Outcomes in Renal Transplantation- Single Centre Experience
O. Piscoran¹, J. Worthington², R. Dhillon¹, T. Augustine¹, M. Picton¹, M. Morton¹, S. Bhutani¹
¹Urology, Renal and Transplantation, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, United Kingdom
*Purpose: Data on the role of HLA-DP antibodies on graft outcome is not precise. Studies suggested that the presence of donor-directed HLA-DP antibodies correlate with…
2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
D. Xu¹, K. Richards¹, K. Zheng¹, H. Patel², F. Cardarelli², J. A. Pena³, A. Aala²
¹Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ³Pathology, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…
2021 American Transplant Congress
DSA is Associated with Molecular Changes in Many Hearts with Minor Abnormalities but Not Diagnosed as Antibody-Mediated Rejection
P. Halloran¹, K. S. Madill-Thomsen¹, &. the INTERHEART Study Group²
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²., ., AB, Canada
*Purpose: We previously developed a microarray-based diagnostic system (MMDx) for heart transplant endomyocardial biopsies, measuring gene expression and interpreting antibody-mediated and T cell-mediated rejection (ABMR,…
2021 American Transplant Congress
Disparities in HLA Representation by Single Antigen Reagents in Different Ethnic Populations
J. C. Quon¹, J. Menteer², N. Fotiadis², R. M. Lestz², L. A. Baxter-Lowe²
¹Keck School of Medicine of USC, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
*Purpose: It is not possible to test for antibodies against the antigens encoded by every HLA allele due to cost and throughput constraints. When alleles…
2021 American Transplant Congress
Donor-specific Anti-HLA Alloantibody in Kidney Transplant Recipients with COVID-19 Exhibit a Different Immunoglobulin Class and Subclass Profile When Compared to Anti-SARS-CoV-2 Antibodies
A. Girnita¹, L. Wang¹, M. Fernandez-Vina¹, E. Woodle², P. Ahearn¹, T. Yalamarti¹, M. Menon³, Y. Azzi⁴, M. Melcher¹, R. Bray⁵, H. Gebel⁵, E. Akalin⁴, P. Cravedi³, J. S. Maltzman¹
¹Stanford University, Palo Alto, CA, ²University of Cincinnati, Cincinnati, OH, ³Icahn School of Medicine, NYC, NY, ⁴Einstein School of Medicine, NYC, NY, ⁵Emory University, Atlanta, GA
*Purpose: Both anti-HLA and anti-SARS-CoV-2 antibodies target protein antigens. The aim of the present study was to compare the class and subclass profile of such…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…
2021 American Transplant Congress
The Impact of Maintenance Immunosuppression Withdrawal on Sensitization Status After Renal Graft Failure
R. Hod Dvorai, A. Almonte, C. Hubbell, M. Laftavi, R. Shahbazov, R. Saidi, O. Pankewycz, J. Leggat, M. Hanlon, B. Gallay
SUNY Upstate Medical University, Syracuse, NY
*Purpose: Maintaining immunosuppression (IS) following failed renal transplant may lead to increased risk for infections and malignancies; on the other hand, withdrawal can lead to…
2020 American Transplant Congress
A Single-Center Analysis of Using Allele-Level 11 HLA Loci Information on cPRA and Organ-Allocation Points in Kidney Transplant Candidates
C. Maguire¹, P. Muluhngwi¹, E. Kransdorf², L. Gragert³, A. R. Tambur¹
¹Northwestern University, Chicago, IL, ²Cedars-Sinai Heart Institute, Beverly Hills, CA, ³Tulane University, New Orleans, LA
*Purpose: Calculated panel reactive antibodies (cPRA) is used by the United Network for Organ Sharing (UNOS) to quantify degree of HLA sensitization and assign priority…

« Previous Page
1
…
5
6
7
8
9
…
47
Next Page »